{'fraction_non_alphanumeric': 0.04279069767441861, 'fraction_numerical': 0.014883720930232559, 'mean_word_length': 4.977777777777778, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognostic Factors and Clinical Characteristics of Chronic Hepatitis B with or without Nucleos(t)ide Analogues Therapy: A Retrospective Study.

OBJECTIVE
We compared the prognostic factors and clinical characteristics of chronic hepatitis B (CHB) patients who received nucleos(t)ide analogues (NAs) therapy to those who did not.


METHOD
A total of 315 CHB patients were enrolled in this study and were divided into NA (n=144) and non-NA (n=171) groups based on their therapy.


RESULTS
The risk of hepatocellular carcinoma (HCC) development and mortality in the NA group were significantly lower than those in the non-NA group. Smoking, alcohol abuse, AFP, γ-GTP, and HBV DNA levels were significantly correlated with hepatocarcinogenesis. Alcohol abuse, AFP, γ-GTP, HBV DNA levels and NA treatment were associated with mortality in these patients.


CONCLUSIONS
NA therapy reduced the risk of HCC and mortality in CHB patients. Smoking, alcohol abuse, AFP >20 ng/mL, HBV DNA >20,000 IU/mL, and elevated γ-GTP serum concentration were significantly related to poor outcomes.